Novavax Inc. (NVAX) has received European marketing authorization for its updated Nuvaxovid COVID-19 vaccine, targeting the JN.1 variant and providing protection against several other variants. This approval marks a significant milestone for the company, although the vaccine hasn’t yet received full FDA approval in the US.